



SDAI Limited
(Company Registration No. 201107179D)
(Incorporated in the Republic of Singapore on 25 March 2011)

FOR IMMEDIATE RELEASE

SDAI Obtains Approval for its Proprietary Plant Stem Cells Skincare Line from the National Medical Products Administration of the People's Republic of China, Marking First Step in the Group's Transformation into a Biotechnology Company

- The 21st century marks a new era in the life science sector and the Group's Bluecode Biotech skincare products utilise biological cells to deliver a new generation of skincare solutions.

SINGAPORE, 30 April 2025 – The board of directors (the “**Board**”) of SDAI Limited (the “**Company**” or “**SDAI**”, and together with its subsidiaries, the “**Group**”) is pleased to announce that the Group has received regulatory approval from the National Medical Products Administration (国家药品监督管理局) of the People's Republic of China to sell its proprietary skincare line, **Bluecode Biotech B-III series (蓝码生物B-III系列)** in the Chinese market. The approved series include two registered products, namely (i) the **Apple Fruit Cell Serum (苹果果实细胞精华液)** and (ii) the **Adenium Obesum Cell Facial Mask (沙漠蔷薇叶细胞面膜)**. This regulatory approval marks a significant milestone in the Group's strategic transformation into a biotechnology-focused company, following a strategic exploration of emerging opportunities in the biotechnology industry.

Transforming into a biotechnology company

The global biotechnology market, valued at US\$1.55 trillion in 2023, is projected to grow at a compound annual growth rate (CAGR) of 13.96% from 2024 to 2030¹. With the growing global emphasis on health and wellness, the biotechnology industry is poised to be a transformative industry in the coming years². The anticipated rapid growth of the industry underscores the industry's immense potential, presenting a timely opportunity for the Group to capitalise on this emerging trend. The Group is of the view that the biotechnology industry has the potential to follow a growth trajectory similar to that of the Internet and artificial intelligence, both of which have revolutionised industry paradigms and reshaped everyday life.

In light of the positive outlook of the biotechnology industry, the Group established a Wholly Foreign-Owned Entity (WFOE), Hainan Blue Code Biotechnology Co., Ltd.,

¹ Biotechnology Market Size & Trends, <https://www.grandviewresearch.com/industry-analysis/biotechnology-market>

² What Will the Life Sciences Industry Look Like in 2030? <https://www.netguru.com/blog/life-sciences-industry-2030#what-to-expect-in-the-life-sciences-industry-in-2030>



SDAI Limited
(Company Registration No. 201107179D)
(Incorporated in the Republic of Singapore on 25 March 2011)

located in the Hainan Boao Lecheng International Medical Tourism Pilot Zone ("**Lecheng Pilot Zone**"), to focus on conducting research and operational activities in relation to future biotechnology and stem cells development. Located in Boao Town, Qionghai City, Hainan Province, the Lecheng Pilot Zone was approved by the State Council in February 2013 and is currently the only "Special Medical Zone" in China.

Revolutionising plant stem cells skincare with advanced technology

The Group's first step in this transformative journey will be launching the Bluecode Biotech B-III series plant stem cell skincare products.

Life sciences have become the foundation of modern skincare, revealing fundamental insights into aging in the 21st century. As scientific research advances, skin health has become a vital focus in the field of life sciences. The key areas of research now include how to stimulate communication between skin cells to achieve effective, yet straightforward, skincare solutions. This has become the primary research direction for Bluecode Biotech's B-III series of skincare products.

Under the Bluecode Biotech B-III brand, the Group is ushering in a new era of skincare. The first product in this line is a serum enriched with Uttwiler Spätlauber apple stem cells³, derived from a rare Swiss apple variety known for its extraordinary shelf life and regenerative qualities. This unique apple can remain fresh for months without shrivelling or refrigeration, making it an ideal source for regenerative skincare.

There are over 20 million biological specimens in nature, forming an abundant supply base. Advances in 21st century life sciences have demonstrated that all life activities stem from communication between cells, whether in plants or in animals. Cells are the basic building blocks and functional units of all living organisms, with new cells created through the division of existing ones. The death of cells is a natural part of aging and marks the end of their life cycle.

Research on skin cell aging is just one aspect of the broader scientific study of the human aging. The Bluecode Biotech B-III skincare products examine the phenomenon, processes, and underlying principles of skin aging. This involves exploring the characteristics, causes, and mechanisms behind aging to identify strategies for delaying aging and fundamentally slowing down skin aging.

The Group aims to establish itself as a leader in biotechnology through its breakthrough work in cellular rejuvenation.

³ Uttwiler Spätlauber apple stem cells, <https://www.swissinfo.ch/eng/banking-fintech/a-swiss-apple-a-day-keeps-wrinkles-at-bay/7668056>



SDAI Limited
(Company Registration No. 201107179D)
(Incorporated in the Republic of Singapore on 25 March 2011)

Madam Hao Dongting (郝东亭), Executive Chairperson of the Company, commented, "The transformation journey of the Company has been challenging, particularly in identifying sustainable and profitable business opportunities to inject into the Group amidst a challenging macroeconomic environment. However, with unwavering determination, our team has identified promising growth prospects within the biotechnology industry.

We are thrilled to have received regulatory approval to sell our Bluecode Biotech B-III skincare series in China. This regulatory approval marks a key milestone in our transition to a biotechnology-driven company. This approval represents the first step in our broader strategy to offer consumers truly innovative solutions for health and wellness."

- END -

About SDAI Limited

Listed on the Catalist Board of the Singapore Exchange since July 2011, SDAI Limited ("SDAI", and together with its subsidiaries, the "**Group**") is a company listed on the Catalist Board of the Singapore Exchange since July 2011, is undergoing a strategic transformation into a biotechnology company specialising in healthcare-related products and services.

As the first step in its biotechnology-driven transformation, the Group has launched the Bluecode Biotech B-III skincare series, an advanced line of plant stem cell skincare products.

The Group plans to integrate biotechnology across the medical, skincare, and health products industries, and is committed to become a leading force in the biotechnology space.

For more information, please visit www.sdai.com.sg

**Issued for and on behalf of SDAI Limited
by Woodnote Consulting**

Yong Jing Wen

E: jingwen@woodnoteconsulting.com

T: (65) 9860 3047



SDAI Limited
(Company Registration No. 201107179D)
(Incorporated in the Republic of Singapore on 25 March 2011)

*This press release has been reviewed by the Company's sponsor, ZICO Capital Pte. Ltd. (the "**Sponsor**").*

*This press release has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.*

The contact person for the Sponsor is Ms Yang Zhenni, ZICO Capital Pte. Ltd. at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, telephone (65) 6636 4201.